Organogenesis readies new expansion plans

With the first phase of its expansion plan complete, Canton, MA-based Organogenesis is now blueprinting a new R&D center and manufacturing plant. The biotech says that it will have invested $63 million in the expansion by the time it is all completed in 2013. The developer also says that Saudi officials have approved its treatment for chronic wounds and foot ulcers. Story

Suggested Articles

In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot.

In our EuroBiotech roundup this week, NEC and Vaximm ink cancer vaccine pact, Compugen posts cancer data and Lunac raises cash.

Biotech venture fund ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new JV.